Ms. Susanna Uusmaa is a biomedical scientist with broad expertise in Medical Sciences and in International Business. Holding an MSBS degree, she is results-driven to integrate modern smart technologies into making substantive contributions to the biomedical sector.

Having conducted research in neuroscience and oncology and having proudly graduated from Tallinn University of Technology (TALTECH) and Tallinn University School of Natural Sciences and Health, Ms. Uusmaa takes an evidence-based approach to her professional objectives and also to her endeavors as a passionate healthy lifestyle entrepreneuse.

With a background in biomolecular and medical sciences, she has recently co-founded Quantum Brain Research Institute with the aim of supporting the development of neuroscientific research for neurocritical treatment applications through instructive programs in mental health assessment and management. She is also the Chief Science Officer and Co-Founding Partner of Nutrily™ | Health & Wellness Builders, a dietary supplements, nutritional products, and sportswear European corporation established in Tallinn, Estonia. Additionally, she is the CSO & Co-Founding Partner of RegenerAge®Elite Clinic.

In collaboration with the Luxembourg Institute of Health and Luxembourg Centre for Systems Biomedicine, she developed a complete standard operating procedure for differentiating and generating fully functional glial cells from induced pluripotent stem cells (iPSCs) in only 30 days.

Ms. Susanna Uusmaa is the Chairwoman of the WAMS National Council of Estonia, Member of the Academy Faculty, Fellow of the Academy, Member of the WAMS Education and Training Board (ETB), a Member of the WAMS Coronavirus Committee, and a Member of the WAMS Executive Council.

Moreover, she holds over 6 years of hard-working experience in business operations and relationship building in more than 5 countries around the globe, having created and nurtured mutually beneficial partnerships, enhanced workflow efficiency, and contributed to the growth of several initiatives with substantial savings.

Ms. Uusmaa’s biomedical undertakings have positioned her as an MSBS to be able to become an active contributor also to the longevity sector and put her expertise into helping people become their best version of themselves with properly validated and ethical practices.

M. M. Karindas is the President of the WAMS, The World Academy of Medical Sciences, where he has been serving for more than two decades now. He is also Editor-in-Chief of the Journal of Oncobiomarkers, Associate Editor of the American Journal of Biomedicine, and on the Editorial Board of the Journal of Cancer Sciences.

Having extensive experience as a research scientist in Clinical and Molecular Oncology, he is the holder of landmark theories including the Multicellular Origin of Cancer and “Oncogenetic Evolution” as well as the OCAT and ECE theories. He is also the creator and writer of the KGS, the Karindas Grading System, the all-encompassing universal paradigm of tumor grading and a new integral method of clinical management in oncology.

Dr. Karindas’ main research interests are oncogenesis, metastasis, cancer stem cells, tumor cell biology, molecular oncopathology, cell signaling, signal transduction, extracellular matrix, and the origin and evolution of cancer. He is currently busy working on the creation and establishment of a new medical algorithmic system that will universally be used in oncology and all other fields of medicine.

ABSTRACT:

The Karindas Grading System (KGS): Integrating Regenerative Medicine for a Comprehensive Understanding of Cancer Origins

In the field of oncohistopathology and oncobiopathology, grading systems play a crucial role in assessing tumor characteristics, guiding prognostic evaluations, and informing therapeutic decisions. However, the existing grading systems have limitations in interpretation, application, and uniformity. To address these challenges, we present the Karindas Grading System (KGS), a novel and comprehensive approach that integrates regenerative medicine concepts to revolutionize our understanding of cancer origins.

This presentation begins with an overview of the current grading systems used in oncohistopathology and oncobiopathology. These systems often rely on three-tier scales based on histologic characteristics, including parameters like mitotic activity and tumor necrosis. While practical, these systems have limited boundaries and lack the efficiency required for effective clinical case management and research studies.

We then introduce the development of the Karindas Grading System (KGS) in the context of regenerative medicine. The KGS aims to provide a more holistic assessment of tumor cells by examining their maturation, differentiation, and alterations, as well as evaluating their cellular activities and organization. By incorporating regenerative medicine concepts, the KGS offers a deeper understanding of phenotypic and genotypic descriptions in vivo, enabling precision diagnostics, prognostic evaluation, and tailored therapies.

The role of the KGS extends beyond individual tumor cells to assess tissue identities within the context of cancer progression. It offers insights into the dynamic interactions between cancer cells and their microenvironment, with implications for regenerative medicine research and the development of innovative therapy approaches.

In clinical practice, the KGS has significant applications. It can be integrated into tumor staging and prognostic evaluation, providing clinicians with a more comprehensive and informative assessment of patient cases. Additionally, the KGS enhances personalized treatment approaches, leveraging regenerative medicine techniques to optimize therapeutic decision-making for improved patient outcomes. Case examples showcase the practical application of the KGS, highlighting its potential in guiding clinical management.

Furthermore, the KGS unveils the obscure corners of oncogenesis, contributing to a better understanding of the underlying processes. It aids in identifying key factors and mechanisms involved in cancer development, paving the way for targeted interventions and regenerative medicine-based therapies.

Dr. Walter Bini, MD, PhD, is a distinguished Senior Consultant Neurosurgeon at Healthpoint Hospital in Abu Dhabi, UAE. With a remarkable career path that includes a close collaboration with the esteemed Prof. Dr. Madjid Samii in Hannover, Germany, Dr. Bini has established himself as an authority in the field of neurosurgery.

Dr. Bini’s expertise extends to various subfields within neurosurgery, encompassing general micro neurosurgery, the management of head trauma, neurooncology, stereotaxy and radiosurgery, as well as spinal surgery, including less invasive techniques and neuroradiology. His dedication and passion for these specialized areas have solidified his reputation as a leading authority in the field.

Notably, Dr. Bini has been serving as the Middle East Chairman of the International Society for the Advancement of Spine Surgery (ISLASS) since 2014, demonstrating his commitment to advancing spinal surgery practices in the region. Moreover, he actively contributes to the field as an active member and board member of various international societies, including the Skull Base Study Group, the German Neurosurgical Society (SAS), the American Association of Neurological Surgeons (AANS), and others.

In addition to his expertise in neurosurgery, Dr. Bini possesses impressive linguistic skills. He is fluent in English, German, Spanish, Italian, and has a working knowledge of French. These language abilities allow him to effectively communicate with patients from diverse backgrounds, fostering trust and understanding.

Dr. Bini’s contributions to the medical field extend beyond his clinical practice. Since 2017, he has served as the Lead Neurosurgeon at the Waldkrankenhaus for Special Surgeries in Leipzig, Germany, specifically focusing on trauma, sports-related injuries, and spine-related conditions. Furthermore, Dr. Bini holds an executive board member position and serves as the Dean of the Faculty of the World Academy of Medical Sciences (WAMS), reflecting his commitment to academic excellence and fostering future generations of medical professionals. Additionally, he holds a faculty position at the London Medical Education Academy in the United Kingdom, further showcasing his dedication to medical education and knowledge dissemination.

Dr. Walter Bini’s extensive experience, exceptional skills, and contributions to the field of neurosurgery have solidified his reputation as an eminent neurosurgeon. His remarkable achievements and multifaceted roles as a clinician, researcher, educator, and leader continue to shape the landscape of neurosurgical practice, making him a respected figure among colleagues and an invaluable asset to the medical community.

ABSTRACT:

Adipose-derived Mesenchymal Stem Cells in the Treatment of Degenerative Spine Conditions: Protocol and personal experience with DDD

Lumbar degenerative disc disease (DDD) poses an ongoing challenge as far as treatment options and alternatives, especially when considering younger patients. Over 80% of the adult population presents with one or more episodes of ongoing-progressive low-back pain (LBP). The primary cause is associated with degeneration of the intervertebral disc and which is triggered by a decrease in the nucleus pulposus cell population, as evidenced in histological studies. Definitely, in the presence of a “black disc” without profusion and neurological compromise, microsurgery or even fusion surgery should not be contemplated. Numerous percutaneous techniques have been propagated as the proper way to treat this condition throughout the literature in the past years. They have been primarily focused on the treatment of the pain generated by the involved disc and the subsequent segmental insufficiency, without addressing the degeneration of the disc and for this have had limited success and remain as pain management tools. Some significant trials in the past (i.e. Chondrocyte transplantation trial) and the increasing recent research and achievements with more biological strategies as far as tissue regeneration has motivated the development of a new treatment concept initially applicable to the lumbar spine which will be presented and discussed.

Advancements have led to a significant improvement in the understanding of the cell environment and tissue transplantation at a molecular, cellular and immunobiological level. Adipose tissue has already become a central source of clinical and research work involving adipose tissue-derived progenitor cells. Endothelial and mesenchymal stem cells derived from adipose tissue are being considered and used in an array of clinical conditions and seem to have clear therapeutic benefits for many disease conditions including those affecting bone, cartilage and muscle. The use of an accessible source with abundant cells which have a high potential for regeneration clearly is superior in comparison to the chondrocyte option for the lumbar disc. Mesenchymal cells have a high self-renewal capacity and a potential for multi-lineage differentiation. For this, adipose tissue-derived MSCs (ADMSCs) are optimal candidates for tissue regeneration and can be obtained from the patient in a one-step procedure treatment.

Dr. Mohammad Azfar, MS, FACS, FRCSEd, is an esteemed medical professional specializing in General and GI surgery. With an impressive background and extensive experience, Dr. Azfar’s contributions to the field have made a significant impact on patient care and surgical advancements.

Throughout his career, Dr. Azfar has been actively involved in the care of trauma patients, particularly those affected by high-velocity Motor Vehicle Accidents, as well as Surgical Critical Care. His expertise extends to various procedures, including Upper Gastrointestinal Endoscopy (EGD), Lower GI Endoscopy (Colonoscopy), PEG Placement, Reinsertion, Endoscopic Variceal Ligation (EVL), Capsule Endoscopy, Anorectal Manometry, and Advanced Wound Care and Management. He has also been involved in a bariatric surgery program, where he has gained proficiency in Intragastric Endoscopic Balloon Insertion and Dilatation of Strictures Post LRAYGB. While these achievements demonstrate his versatility, Dr. Azfar’s primary interests lie in minimally invasive surgery for anorectal disorders, utilizing techniques such as VAAFT, EPSiT, harmonic hemorrhoidectomy, and Laser application in the treatment of fistula, hemorrhoids, varicose veins, and pelvic floor disorders. Trauma and Surgical Intensive Care, as well as Surgical Nutrition, continue to be his areas of special interest.

Dr. Azfar’s dedication to advancing medical knowledge is evident through his 35 publications in national and international journals, covering a wide range of topics in General and GI surgery. Notably, he serves as the international editor of the Surgical Recall Series (Editions 3rd through 9th) by Lipincott Williams and Wilkins, Baltimore, USA, and is a valued member of several editorial boards for surgical publications.

Currently, Dr. Azfar holds the position of Consultant General Surgeon at Burjeel Holdings, LLH Hospital Musaffah Abu Dhabi, UAE. He has previously served as a Consultant Surgeon at Somerian Health and the Advanced Center for Daycare Surgery. His impressive achievements include being the former President of the ACS UAE Chapter of the American College of Surgeons, former Vice President of the ACS UAE Chapter of the American College of Surgeons, former Consultant Surgeon, Head of General Surgery, and Acting Chief of Service at Al Rahba Hospital (Managed by Johns Hopkins Medical International).

Dr. Azfar’s educational journey has equipped him with the knowledge and skills necessary for his outstanding career. He holds a Fellowship from The Royal College of Surgeons, Edinburgh, UK (FRCSEd), a Fellowship in General Surgery from the American College of Surgeons (FACS), and a Master in Surgery (MS) from JN Medical College, India. He also completed his MBBS and MS (Surgery) at JN Medical College, India.

ABSTRACT:

Regenerative Medicine in Gastrointestinal Disorders: Unlocking the Potential for Tissue Restoration and Improved Patient Outcomes

Gastrointestinal disorders pose significant challenges in the realm of medical management, necessitating innovative approaches to address the complex pathophysiology and associated impact on patients’ quality of life. Regenerative medicine has emerged as a transformative field offering promising therapeutic strategies for gastrointestinal disorders. This keynote presentation provides a comprehensive overview of the intersection between gastrointestinal medicine and regenerative medicine, delving into the fundamental principles, potential applications, and translational challenges that lie ahead.

The presentation begins with an introduction, setting the stage for an exploration of the importance of regenerative medicine in gastrointestinal disorders. The current state of gastrointestinal medicine is then elucidated, highlighting the prevailing treatment approaches and their limitations. Building upon this foundation, the subsequent sections delve into understanding gastrointestinal disorders, encompassing an overview of common conditions, their pathophysiology, and the profound impact they exert on patients’ quality of life. Notably, the challenges faced by current treatment approaches are examined, underscoring the imperative for novel therapeutic modalities.

The heart of the presentation lies in the comprehensive exploration of regenerative medicine in gastrointestinal disorders. The fundamentals of regenerative medicine are elucidated, focusing on the key benefits and potential applications in the context of gastrointestinal complications. The underlying principles and techniques involved in regenerative therapies are detailed, shedding light on tissue engineering, stem cell biology, gene editing, and biomaterial sciences.

Furthermore, the presentation delves into in-depth therapeutic approaches within the realm of regenerative medicine for gastrointestinal complications. Specific strategies, such as tissue-specific organoids, organ-on-a-chip models, and bioprinting technologies, are explored as means to advance our understanding of gastrointestinal physiology and pathology. Moreover, the integration of regenerative therapies with conventional treatment modalities is examined, emphasizing the potential for synergistic effects and improved patient outcomes.

As the field progresses, the presentation addresses the translational challenges and future directions of regenerative therapies in gastrointestinal medicine. Safety and efficacy considerations, standardization and quality control measures, delivery strategies, integration with existing therapies, and cost-effectiveness and accessibility concerns are explored. Promising avenues for future research, including the utilization of artificial intelligence and machine learning, are highlighted, underscoring the need for multidisciplinary collaboration and innovative thinking to propel the field forward.

This keynote presentation serves as a comprehensive guide to the multifaceted landscape of regenerative medicine in gastrointestinal disorders. It underscores the potential of regenerative therapies to revolutionize patient care by not only mitigating symptoms but also by restoring tissue function and ultimately improving the quality of life for those afflicted by gastrointestinal conditions. By addressing the translational challenges and charting future directions, we pave the way for a regenerative future that holds immense promise for patients worldwide.